Meperidine Market to Reach $2.04 Billion by 2035

Meperidine market was valued at $1.30 billion in 2025 and is projected to reach $2.04 billion by 2035, growing at a CAGR of 4.6% during the forecast period (2026–2035). The increasing volume of surgical procedures and hospital-based pain management requirements is strengthening demand for opioid analgesics such as meperidine across healthcare systems. According to the World Health Organization, surgical care accounts for nearly 30% of the global burden of disease, with an estimated 313 million surgical procedures performed annually worldwide, directly supporting the need for effective perioperative pain management drugs. Hospitals remain the dominant end-user segment due to the controlled administration requirements of opioid medications and their role in managing acute and postoperative pain. The U.S. Food and Drug Administration emphasizes that opioid analgesics continue to be used under strict clinical supervision for short-term pain management, particularly in surgical recovery and trauma care. The growing number of inpatient and outpatient surgical procedures is increasing demand for fast-acting injectable analgesics such as meperidine.

Browse the full report description of “Meperidine Market Size, Share & Trends Analysis Report, By Product Type (Injectable Meperidine, Oral Meperidine (Tablets / Syrup)), By End-User (Hospitals, Ambulatory Surgical Centers (ASCs), Clinics, Homecare Settings), By Manufacturing Type (Branded Meperidine, Generic Meperidine), By Packaging Type (Ampoules / Vials (Injectables), Blister Packs (Tablets), Bottles (Liquid formulations)), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/meperidine-market

Expansion of Ambulatory Surgical Centers Supporting Market Growth

Ambulatory surgical centers (ASCs) are contributing significantly to market expansion due to the global shift toward outpatient procedures. Healthcare systems are increasingly adopting ASCs to reduce costs and improve patient throughput. This trend is supporting the use of short-duration analgesics like meperidine, particularly in minor surgical interventions where rapid recovery and discharge are required. The injectable meperidine segment holds the largest market share due to its rapid onset of action and effectiveness in emergency and perioperative settings. Ampoules and vials are the most preferred packaging formats in hospitals due to ease of administration and dosage control. Oral formulations, including tablets and syrups, are used in limited clinical scenarios due to regulatory restrictions and lower preference compared to safer alternatives.

Generic Drug Penetration Enhancing Accessibility

Generic meperidine dominates the market owing to cost advantages and widespread availability across hospital systems, particularly in developing regions. Governments and healthcare providers are focusing on reducing treatment costs, which is accelerating the adoption of generic opioid formulations. Branded variants maintain a smaller share due to pricing pressure and regulatory scrutiny.

Strategic Developments Strengthening Market Position

Key manufacturers are adopting strategies such as capacity expansion, regulatory compliance, and portfolio optimization to sustain market presence.

• In February 2026, Teva Pharmaceuticals and Sanofi reported positive results from the RELIEVE UCCD long-term extension study of duvakitug, demonstrating sustained clinical and endoscopic efficacy over 44 weeks in patients with ulcerative colitis and Crohn’s disease. The Phase 2b data reinforces TL1A as a promising therapeutic target and supports further development of duvakitug as a potential best-in-class treatment for inflammatory bowel diseases.
• In January 2026, Teva and Royalty Pharma entered a funding agreement of up to $500 million to support the clinical development of TEV-‘408, an anti-IL-15 antibody targeting autoimmune diseases including vitiligo. The collaboration includes Phase 2b study funding and potential Phase 3 co-development, strengthening Teva’s pipeline expansion and accelerating innovation in immune-mediated therapies.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• By Product Type
• By End-User
• By Manufacturing Type
• By Packaging Type
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape – Pfizer Inc., Hikma Pharmaceuticals, Mallinckrodt Pharmaceuticals, Sanofi S.A., Teva Pharmaceutical Industries, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Meperidine Market Segmentation

By Product Type

• Injectable Meperidine
• Oral Meperidine (Tablets / Syrup)

By End-User

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Clinics
• Homecare Settings

By Manufacturing Type

• Branded Meperidine
• Generic Meperidine

By Packaging Type

• Ampoules / Vials (Injectables)
• Blister Packs (Tablets)
• Bottles (Liquid formulations)

Global Meperidine Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• RussiaRest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/meperidine-market